Phase 1 Trial of AMA1-C1/Alhydrogel plus CPG 7909: An Asexual Blood-Stage Vaccine for Plasmodium falciparum Malaria
Gregory E. D. Mullen, Ruth D. Ellis, Kazutoyo Miura et al. · 2008
Read Phase 1 Trial of AMA1-C1/Alhydrogel plus CPG 7909: An Asexual Blood-Stage Vaccine for Plasmodium falciparum Malaria by Gregory E. D. Mullen, Ruth D. Ellis, Kazutoyo Miura et al. (2008) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0002940.txt.
Description
Gregory Mullen, Ruth Ellis, Kazutoyo Miura and co-authors ran a first human trial of a malaria vaccine mix in 2008. The vaccine targets AMA1, a surface protein of the malaria parasite's blood stage, and pairs it with the adjuvant CPG 7909 to boost response. AMA1 was a leading blood-stage candidate.
This phase 1 trial in PLOS ONE tested safety and immune response for the AMA1 vaccine on Alhydrogel plus the new adjuvant. Phase 1 is the earliest human stage, focused on safety. Malaria vaccine research needs such careful steps, since blood-stage infection is what makes people ill.
Catalog record
| CREATOR | Gregory E. D. Mullen, Ruth D. Ellis, Kazutoyo Miura et al. |
|---|---|
| YEAR | 2008 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 52 KB |
| LICENSE | Creative Commons CC0 License |
| RIGHTS | CC0 |
| SOURCE | PLOS ONE |
Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0002940